Clinical Trials

A completed Phase II clinical trial evaluated D-Tagatose for human therapeutic applications in patients with type 2 diabetes. Sponsored through a collaboration involving academic institutions and commercial entities—including the University of Kentucky, Spherix Incorporated, and investigator Robert Lodder—the study assessed the compound's safety profile and dose-ranging effects on glycemic control over an extended intervention period. Overall, the clinical landscape for D-Tagatose reflects a targeted investigation to establish efficacy and safety parameters for metabolic disease management.

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00961662 Completed
Type 2 Diabetes
Robert Lodder|University of Kentucky|Spherix Incorporated
2008-02 Phase 2

(data from https://clinicaltrials.gov, updated on 2024-05-22)

Check the D-Tagatose product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

D-Tagatose functions as a stereoisomer of fructose that inhibits hepatic glycogen phosphorylase and intestinal glycosidases, thereby suppressing hepatic glycogenolysis and slowing mucosal carbohydrate digestion. This attenuation of postprandial glucose absorption and endogenous hepatic glucose production facilitates improved systemic glycemic regulation, providing a mechanistic rationale for its clinical evaluation in type 2 diabetes.

Appendix RUO and cGMP Quality Standards

Quality Dimension RUO (Research Use Only) cGMP (Current Good Manufacturing Practice)
Clinical Applicability Prohibited in human clinical trials or medical diagnostics. Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status Non-regulated grade; exempt from drug manufacturing laws. Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment Unclassified analytical or research laboratories. Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control Basic purity and activity testing. Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation Basic equipment calibration; no process validation required. Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance Vendor self-declared without required formal QMS. Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact High risk of IND rejection if used as a critical raw material. Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).

Jump to

Note: Technical data last updated: Sep 1, 2026.